You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study
|
|---|---|
| Published in |
BMC Infectious Diseases, April 2018
|
| DOI | 10.1186/s12879-018-3096-7 |
| Pubmed ID | |
| Authors |
Angel Vila-Corcoles, Olga Ochoa-Gondar, Cinta de Diego, Eva Satue, María Aragón, Angel Vila-Rovira, Frederic Gomez-Bertomeu, Ramon Magarolas, Enric Figuerola-Massana, Xavier Raga, Mar O. Perez, Frederic Ballester |
| Abstract |
Benefits using the 13-valent pneumococcal conjugate vaccine (PCV13) in adults are controversial. This study investigated clinical effectiveness of PCV13 vaccination in preventing hospitalisation from pneumonia among middle-aged and older adults. Population-based cohort study involving 2,025,730 individuals ≥50 years in Catalonia, Spain, who were prospectively followed from 01/01/2015 to 31/12/2015. Primary outcomes were hospitalisation for pneumococcal or all-cause pneumonia and death from any cause. Cox regression models were used to evaluate the association between PCV13 vaccination and the risk of each outcome, adjusting for age, sex and major comorbidities/underlying risk conditions. Cohort members were observed for a total of 1,990,701 person-years, of which 6912 person-years were PCV13 vaccinated. Overall, crude incidence rates (per 100,000 person-years) were 82.8 (95% confidence interval [CI]: 77.7-88.1) for pneumococcal pneumonia, 637.9 (95% CI: 599.0-678.7) for all-cause pneumonia and 2367.2 (95% CI: 2222.8-2518.7) for all-cause death. After multivariable adjustments we found that the PCV13 vaccination did not alter significantly the risk of pneumococcal pneumonia (multivariable-adjusted hazard ratio [mHR]: 1.17; 95% CI: 0.75-1.83; p = 0.493) and all-cause death (mHR: 1.07; 95% CI: 0.97-1.18; p = 0.190), although it remained significantly associated with an increased risk of all-cause pneumonia (mHR: 1.69; 95% CI: 1.48-1.94; p < 0.001). In stratified analyses focused on middle-aged or elderly persons and immunocompromised or immunocompetent subjects, PCV13 vaccination did not appear effective either. Our data does not support clinical benefits of PCV13 vaccination against pneumonia among adults in Catalonia. It must be closely monitored in future studies involving more vaccinated person-time at-observation. |
X Demographics
The data shown below were collected from the profiles of 115 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 19 | 17% |
| Spain | 10 | 9% |
| United Kingdom | 3 | 3% |
| Canada | 3 | 3% |
| Italy | 2 | 2% |
| Australia | 2 | 2% |
| India | 1 | <1% |
| Japan | 1 | <1% |
| South Africa | 1 | <1% |
| Other | 4 | 3% |
| Unknown | 69 | 60% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 103 | 90% |
| Scientists | 7 | 6% |
| Practitioners (doctors, other healthcare professionals) | 5 | 4% |
Mendeley readers
The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 37 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 8 | 22% |
| Student > Bachelor | 5 | 14% |
| Student > Master | 4 | 11% |
| Student > Doctoral Student | 2 | 5% |
| Student > Ph. D. Student | 2 | 5% |
| Other | 4 | 11% |
| Unknown | 12 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 32% |
| Nursing and Health Professions | 2 | 5% |
| Psychology | 2 | 5% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Computer Science | 1 | 3% |
| Other | 3 | 8% |
| Unknown | 16 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 85. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 January 2024.
All research outputs
#512,580
of 25,782,229 outputs
Outputs from BMC Infectious Diseases
#125
of 8,704 outputs
Outputs of similar age
#11,251
of 340,701 outputs
Outputs of similar age from BMC Infectious Diseases
#2
of 142 outputs
Altmetric has tracked 25,782,229 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,704 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.7. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 340,701 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 142 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.